<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605252</url>
  </required_header>
  <id_info>
    <org_study_id>3rd-sysu-hbv-functional cure</org_study_id>
    <nct_id>NCT02605252</nct_id>
  </id_info>
  <brief_title>New Strategy Study of Functional Cure of Chronic Hepatitis B</brief_title>
  <official_title>A Study on Optimizing HBsAg Clearance in CHB Patients With Sequential Treatment of Pegylated Interferon Alpha-2b and Nucleoside Analogues</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As HBsAg clearance is uncommon in chronic hepatitis B (CHB) patients on nucleoside analogues
      (NAs) therapy. The purpose of this study is to optimize HBsAg clearance in CHB Patients with
      sequential treatment of pegylated interferon alpha-2b and NAs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CHB Patients who had received, and responded to, NAs for more than 12 months are switched to
      receive peginterferon alfa-2b 80 micrograms/week for 48 weeks and follow up for 48 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBsAg loss</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>CHB patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg &lt;1500 IU/ mL and Hepatitis B virus DNA not detectable, are to receive peginterferon alfa-2b 80 micrograms/week for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2b</intervention_name>
    <description>peginterferon alfa-2b 80 micrograms/week for 48 weeks</description>
    <arm_group_label>CHB patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. CHB patients who had received NAs for more than 12 months.

          2. Hepatitis B e antigen (HBeAg)-negative and anti-HBeAg positive.

          3. Hepatitis B surface antigen (HBsAg) positive and &lt;1500 IU/mL.

          4. Hepatitis B virus DNA not detectable.

        Exclusion Criteria:

          1. Patients with liver cirrhosis, Hepatocellular Carcinoma or other malignancies.

          2. Patients with other factors causing liver diseases.

          3. Pregnant and lactating women.

          4. Patients with concomitant HIV infection or congenital immune deficiency diseases.

          5. Patients with diabetes, autoimmune diseases.

          6. Patients with important organ dysfunctions.

          7. Patients with serious complications ( e.g., infection, hepatic encephalopathy,
             hepatorenal syndrome, gastrointestinal bleeding. )

          8. Patients who receive antineoplastic or immunomodulatory therapy in the past 12 months.

          9. Patients who can't come back to clinic for follow-up on schedule.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiang Zhu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiang Zhu, Doctor</last_name>
    <phone>+86-20-85252373</phone>
    <email>0628zhuxiang@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The third affiliated hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Zhu, Doctor</last_name>
      <phone>13826452564</phone>
      <email>0628zhuxiang@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2015</study_first_submitted>
  <study_first_submitted_qc>November 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2015</study_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Xiang Zhu</investigator_full_name>
    <investigator_title>Attending Physician</investigator_title>
  </responsible_party>
  <keyword>Chronic hepatitis B</keyword>
  <keyword>Peginterferon alfa-2b</keyword>
  <keyword>Nucleotide analogue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

